Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004-2009

Vaccine

Volumn 29, Issue 40, 2011, Pages 6920-6927

  Williams, S Elizabeth ^a   Klein, Nicola P ^b   Halsey, Neal ^c   Dekker, Cornelia L ^d   Baxter, Roger P ^b   Marchant, Colin D ^e   LaRussa, Philip S ^f   Sparks, Robert C ^a   Tokars, Jerome I ^g   Pahud, Barbara A ^d   Aukes, Laurie ^b   Jakob, Kathleen ^f   Coronel, Silvia ^e   Choi, Howard ^b   Slade, Barbara A ^g   Edwards, Kathryn M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b KAISER PERMANENTE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e BOSTON MEDICAL CENTER   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Adverse event following immunization; Causality

Indexed keywords

ACICLOVIR; ANTICONVULSIVE AGENT; CEFPROZIL; CEFTRIAXONE; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS TOXOID; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

ABSCESS; ACUTE DISEASE; ACUTE DISSEMINATED ENCEPHALOMYELITIS; ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; AMYOTROPHIC LATERAL SCLEROSIS; APPLICATION SITE PAIN; APPLICATION SITE REACTION; APPLICATION SITE SWELLING; ARTICLE; ASEPTIC MENINGITIS; AUTOIMMUNE DISEASE; BELL PALSY; BRAIN BLOOD VESSEL; BRAIN EDEMA; CELLULITIS; CEREBELLAR ATAXIA; CHICKENPOX; CHILD; CHRONIC DIARRHEA; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; COMPLEX REGIONAL PAIN SYNDROME; COUGHING; CRYING; DISEASE EXACERBATION; EMERGENCY WARD; ENCEPHALITIS; ENDOCRINE DISEASE; EPILEPTIC STATE; ERYTHEMA; EVALUATION; FACIAL NERVE PARALYSIS; FAMILY HISTORY; FEBRILE CONVULSION; FEMALE; FEVER; FOLLOW UP; FONTANEL; GASTROINTESTINAL DISEASE; GRAND MAL SEIZURE; GUILLAIN BARRE SYNDROME; HEALTH SURVEY; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; IDIOPATHIC DISEASE; IMMUNIZATION; INFANT; INFLAMMATION; INTENSIVE CARE UNIT; INTUBATION; LIVER DISEASE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL EXPERT; MEDICAL HISTORY; MENINGITIS; MENINGOENCEPHALITIS; MENTAL DISEASE; MENTAL HEALTH; MULTIPLE ORGAN FAILURE; MUSCLE ATROPHY; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MYALGIA; MYELITIS; NEURITIS; POLYNEUROPATHY; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETINITIS; RHINORRHEA; RISK ASSESSMENT; SCHOOL CHILD; SEIZURE; SIDE EFFECT; SKIN DISEASE; SPINAL CORD DISEASE; SYNCOPE; TEMPORAL LOBE EPILEPSY; TONIC CLONIC SEIZURE; TROPICAL DISEASE; URTICARIA; VASCULAR DISEASE; WORLD HEALTH ORGANIZATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CASE-CONTROL STUDIES; DATA COLLECTION; HUMANS; IMMUNIZATION; REFERRAL AND CONSULTATION; VACCINES;

EID: 80052331711     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.044     Document Type: Article

References (60)

1. Alexander L.N., Seward J.F., Santibanez T.A., Pallansch M.A., Kew O.M., Prevots D.R., et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 2004, 292(October (14)):1696-1701.
2. Roush S.W., Murphy T.V. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007, 298(November (18)):2155-2163.
3. Cisse M.F., Breugelmans J.G., Ba M., Diop M.B., Faye P.C., Mhlanga B., et al. The elimination of Haemophilus influenzae type b meningitis following conjugate vaccine introduction in Senegal. Pediatr Infect Dis J 2010, 29(June (6)):499-503.
4. Schoendorf K.C., Adams W.G., Kiely J.L., Wenger J.D. National trends in Haemophilus influenzae meningitis mortality and hospitalization among children, 1980 through 1991. Pediatrics 1994, 93(April (4)):663-668.
5. Fiore A.E., Wasley A., Bell B.P. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55(May (RR-7)):1-23.
6. Van Herck K., Van Damme P. Benefits of early hepatitis B immunization programs for newborns and infants. Pediatr Infect Dis J 2008, 27(October (10)):861-869.
7. Pavia M., Bianco A., Nobile C.G., Marinelli P., Angelillo I.F. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis. Pediatrics 2009, 123(June (6)):e1103-e1110.
8. Poehling K.A., Talbot T.R., Griffin M.R., Craig A.S., Whitney C.G., Zell E., et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006, 295(April (14)):1668-1674.
9. Intussusception among recipients of rotavirus vaccine-United States, 1998-1999. MMWR Morb Mortal Wkly Rep 1999, 48(July 27):577-581.
10. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep 1999, 48(November (43)):1007.
11. Schonberger L.B., Bregman D.J., Sullivan-Bolyai J.Z., Keenlyside R.A., Ziegler D.W., Retailliau H.F., et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979, 110(August (2)):105-123.
12. Woo E.J., Burwen D.R., Gatumu S.N., Ball R. Extensive limb swelling after immunization: reports to the Vaccine Adverse Event Reporting System. Clin Infect Dis 2003, 37(August (3)):351-358.
13. Bonnet M.C., Dutta A., Weinberger C., Plotkin S.A. Mumps vaccine virus strains and aseptic meningitis. Vaccine 2006, 24(November (49-50)):7037-7045.
14. Murphy T.V., Gargiullo P.M., Massoudi M.S., Nelson D.B., Jumaan A.O., Okoro C.A., et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001, 344(February (8)):564-572.
15. Preliminary results: surveillance for Guillain-Barre syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine - United States, 2009-2010. MMWR Morb Mortal Wkly Rep 2010, 59(June (21)):657-661.
16. Bonanni P., Cohet C., Kjaer S.K., Latham N.B., Lambert P.H., Reisinger K., et al. A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD. Vaccine 2010, 28(July (30)):4719-4730.
17. Wharton M. Vaccine safety: current systems and recent findings. Curr Opin Pediatr 2010, 22(February (1)):88-93.
18. Collet J.P., MacDonald N., Cashman N., Pless R. Monitoring signals for vaccine safety: the assessment of individual adverse event reports by an expert advisory committee. Advisory Committee on Causality Assessment. Bull World Health Organ 2000, 78(2):178-185.
19. Chaves S.S., Haber P., Walton K., Wise R.P., Izurieta H.S., Schmid D.S., et al. Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995-2005. J Infect Dis 2008, 197(March (Suppl. 2)):S170-S177.
20. Slade B.A., Leidel L., Vellozzi C., Woo E.J., Hua W., Sutherland A., et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009, 302(August (7)):750-757.
21. Talbot H.K., Keitel W., Cate T.R., Treanor J., Campbell J., Brady R.C., et al. Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine 2008, 26(July (32)):4057-4061.
22. LaRussa P.E.K., Dekker C., Klein N., Halsey N., Marchant C., Baxter R.E.R., et al. Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment (CISA) network. Pediatrics 2011, 127(March (3)). [Vaccine Safety Supplement].
23. CDC. Vaccine Safety - Clinical Immunization Safety Assessment (CISA) Network. 02/25/2010. Available from: [cited 08/04/2010]. http://www.cdc.gov/vaccinesafety/Activities/cisa.html.
24. Rosenberg M., Sparks R., McMahon A., Iskander J., Campbell J.D., Edwards K.M. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age. Vaccine 2009, 27(July (32)):4278-4283.
25. CDC. VAERS - Vaccine adverse event reporting system. Available from: [cited 12/23/2010]. http://vaers.hhs.gov/index.
26. Wise R.P., Iskander J., Pratt R.D., Campbell S., Ball R., Pless R.P., et al. Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine. JAMA 2004, 292(October (14)):1702-1710.
27. Prymula R., Siegrist C.A., Chlibek R., Zemlickova H., Vackova M., Smetana J., et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet 2009, 374(October (9698)):1339-1350.
28. Black S.B.R.P., Lewis E.M., et al. Lower reactogenicity of two different DTaP preparations in young children versus combined DTaP-IPV-Hepatitis B [abstract]. Abstracts of the 43rd Annual Meeting of the Infectious Diseases Society of America 2005, 217.
29. Children's Hospital of Philadelphia. Vaccine Education Center. June 2010. Available from: [cited 10/21/2010]. http://www.chop.edu/service/vaccine-education-center/home.html.
30. Ozkaya E., Mirzoyeva L., Jhaish M.S. Ceftriaxone-induced fixed drug eruption: first report. Am J Clin Dermatol 2008, 9(5):345-347.
31. Hayes E.B. Acute viscerotropic disease following vaccination against yellow fever. Trans R Soc Trop Med Hyg 2007, 101(October (10)):967-971.
32. Martin M., Tsai T.F., Cropp B., Chang G.J., Holmes D.A., Tseng J., et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001, 358(July (9276)):98-104.
33. Kohl K.S., Ball L., Gidudu J., Hammer S.J., Halperin S., Heath P., et al. Abscess at injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007, 25(August (31)):5821-5838.
34. Ghaffar F., Carrick K., Rogers B.B., Margraf L.R., Krisher K., Ramilo O. Disseminated infection with varicella-zoster virus vaccine strain presenting as hepatitis in a child with adenosine deaminase deficiency. Pediatr Infect Dis J 2000, 19(August (8)):764-766.
35. Addition of severe combined immunodeficiency as a contraindication for administration of rotavirus vaccine. MMWR Morb Mortal Wkly Rep 2010, 59(June (22)):687-688.
36. Vestergaard M., Hviid A., Madsen K.M., Wohlfahrt J., Thorsen P., Schendel D., et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA 2004, 292(July (3)):351-357.
37. Adverse events associated with childhood vaccines-evidence bearing on causality 1994, National Academy Press, Washington, DC. K.R. Stratton, C.J. Howe, R.B. Johnston (Eds.).
38. Shaw F.E., Graham D.J., Guess H.A., Milstien J.B., Johnson J.M., Schatz G.C., et al. Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years. Am J Epidemiol 1988, 127(February (2)):337-352.
39. Halperin S.A., Scheifele D., Mills E., Guasparini R., Humphreys G., Barreto L., et al. Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine. Vaccine 2003, 21(June (19-20)):2298-2306.
40. Vilella A., Dal-Re R., Simo D., Garcia-Corbeira P., Diego P., Bayas J.M. Reactogenicity profile of tetanus-diphtheria (adult-type) vaccine: results of a naturalistic study performed at an adult vaccination center. J Clin Pharmacol 2000, 40(November (11)):1267-1273.
41. Sunaga Y., Hikima A., Ostuka T., Morikawa A. Acute cerebellar ataxia with abnormal MRI lesions after varicella vaccination. Pediatr Neurol 1995, 13(November (4)):340-342.
42. Frohman E.M., Wingerchuk D.M. Clinical practice. Transverse myelitis. N Engl J Med 2010, 363(August (6)):564-572.
43. Stratton K.R., Howe C.J., Johnston R.B. Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. JAMA 1994, 271(May (20)):1602-1605.
44. Jefferson T., Rudin M., DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine 2003, 21(May (17-18)):2003-2014.
45. Decker M.D., Edwards K.M., Bogaerts H.H. Combination vaccines. Vaccines 2004, 825-861. Saunders, PL. 4th ed. S.A. Plotkin, W.A. Orenstein (Eds.).
46. Halsey N.A. Combination vaccines: defining and addressing current safety concerns. Clin Infect Dis 2001, 4(December):S312-S318.
47. Black S., Eskola J., Siegrist C.A., Halsey N., Macdonald N., Law B., et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009, 374(December (9707)):2115-2122.
48. Confavreux C., Suissa S., Saddier P., Bourdes V., Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 2001, 344(February (5)):319-326.
49. The Brighton Collaboration. Available from: [cited 10/23/2010]. https://brightoncollaboration.org/internet/en/index.html.
50. Zanoni G., Ferro A., Valsecchi M., Tridente G. The Green Channel of the Veneto region as a model for vaccine safety monitoring in Italy. Vaccine 2005, 23(March (17-18)):2354-2358.
51. Zanoni G., Nguyen T.M., Valsecchi M., Gallo G., Tridente G. Prevention and monitoring of adverse events following immunization: the Green Channel of the Veneto region in Italy. Vaccine 2003, 22(December (2)):194-201.
52. InfoVac. Available from: [cited 12/7/2010]. http://www.infovac.ch/index.php%3FItemid=95.
53. Wood R.A., Berger M., Dreskin S.C., Setse R., Engler R.J., Dekker C.L., et al. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics 2008, 122(September (3)):e771-e777.
54. CDC. Clinical evaluation tools for smallpox vaccine adverse reactions. Available from: [cited 07/01/2010]. http://www.bt.cdc.gov/agent/smallpox/vaccination/clineval/.
55. Cooper L.Z., Larson H.J., Katz S.L. Protecting public trust in immunization. Pediatrics 2008, 122(July (1)):149-153.
56. CDC. Possible side effects from vaccines, 2011 (6/13/2010). Available from: [cited 1/20/2011]. http://www.cdc.gov/vaccines/vac-gen/side-effects.htm%23dtap.
57. Barlow W.E., Davis R.L., Glasser J.W., Rhodes P.H., Thompson R.S., Mullooly J.P., et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 2001, 345(August (9)):656-661.
58. Belsher J.L., Gay P., Brinton M., DellaValla J., Ridenour R., Lanciotti R., et al. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine 2007, 25(December (50)):8480-8485.
59. Whittembury A., Ramirez G., Hernandez H., Ropero A.M., Waterman S., Ticona M., et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 2009, 27(October (43)):5974-5981.
60. Klein N.P., Kissner J., Aguirre A., Sparks R., Campbell S., Edwards K.M., et al. Differential maternal responses to a newly developed vaccine information pamphlet. Vaccine 2009, 28(December (2)):323-328.